ASH 2020 | JULIET trial update: Myc expression and T-cell responses in R/R DLBCL
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the follow-up of the JULIET trial (NCT02445248), whose aim was to evaluate the efficacy of tisa-cel in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients. This latest follow-up focuses on the associations between treatment efficacy and Myc overexpression in the tumor as well as the tumor microenvironment (TME) characteristics. Patients with a Myc- status and a higher frequency of tumor-infiltrating CD3+ T cells were found to have improved outcomes, including longer median progression-free survival (PFS) and overall survival. These findings suggest that Myc overexpression, or an unfavorable immunosuppressive TME, may impact treatment efficacy in patients with DLBCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prof. Ulrich Jäger, MD, has received research support from Bioverativ and Roche and has received honoraria for lecturing or advisory boards from AbbVie, Bioverativ, Gilead, Janssen, Mundipharma, Novartis, Roche and Sandoz.
